Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) reported full-year 2021 results for the year ended 31 December 2021, confirms beating guidance, and, as previously announced, proposes a dividend of €0.95 per share at the next AGM on 27 May 2022.
Business Highlights:
- FDA approved GI Genius™, the first-to-market device that uses artificial intelligence (AI) to assist clinicians in the detection of lesions in the colon in real time during a colonoscopy.
- DETECT study showed AI assistance using GI Genius™ reduces missed polyp rate by over 50% on initial colonoscopy.
- Signed licence and supply agreement between Cassiopea S.p.A. and Sun Pharmaceutical Industries for Winlevi® in the U.S. and Canada.
- Winlevi® launched by Sun Pharmaceutical Industries in the U.S. in November 2021.
- Cosmo launched and successfully closed public exchange offer to acquire Cassiopea S.p.A.
Japan income fund, JPMorgan Japan Small Cap Growth & Income (LONJSGI), targets Japan income without compromising on Japanese growth opportunities. This Japan income investing opportunity gives investors access to a diverse and fast growing sector managed by local managers. The Investment Trust offers a regular quarterly income without compromising on Japanese growth opportunities, by paying a higher dividend funded part by capital reserves as well as revenue returns.